$IONS
IONIS PHARMACEUTICALS INC

2024 Q2 Form 10-Q Financial Statement

#000087401524000142 Filed on May 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $225.3M $119.5M
YoY Change 19.55% -8.45%
Cost Of Revenue $4.164M $2.151M
YoY Change 64.13% 60.16%
Gross Profit $221.1M $117.3M
YoY Change 18.94% -9.16%
Gross Profit Margin 98.15% 98.2%
Selling, General & Admin $65.11M $52.64M
YoY Change 41.11% 15.66%
% of Gross Profit 29.45% 44.86%
Research & Development $222.0M $214.2M
YoY Change -3.45% 8.29%
% of Gross Profit 100.41% 182.55%
Depreciation & Amortization $3.087M $2.547M
YoY Change -5.25% -2.19%
% of Gross Profit 1.4% 2.17%
Operating Expenses $65.11M $52.64M
YoY Change 41.11% 15.66%
Operating Profit -$66.09M -$149.5M
YoY Change -26.72% 30.98%
Interest Expense $4.490M $4.151M
YoY Change 95.98% 158.15%
% of Operating Profit
Other Income/Expense, Net $610.0K $277.0K
YoY Change -94.55% 20.43%
Pretax Income -$66.20M -$142.7M
YoY Change -14.52% 26.37%
Income Tax $100.0K $100.0K
% Of Pretax Income
Net Earnings -$66.27M -$142.8M
YoY Change -22.31% 14.86%
Net Earnings / Revenue -29.42% -119.5%
Basic Earnings Per Share -$0.45 -$0.98
Diluted Earnings Per Share -$0.45 -$0.98
COMMON SHARES
Basic Shares Outstanding 146.0M 145.8M
Diluted Shares Outstanding 146.0M 145.5M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.635B $1.652B
YoY Change -16.84% -7.33%
Cash & Equivalents $294.0M $348.9M
Short-Term Investments $1.341B $1.303B
Other Short-Term Assets $194.7M $174.1M
YoY Change 9.47% 8.98%
Inventory $28.72M $30.26M
Prepaid Expenses
Receivables $27.00M $5.140M
Other Receivables $0.00 $0.00
Total Short-Term Assets $2.329B $2.416B
YoY Change -10.98% -4.99%
LONG-TERM ASSETS
Property, Plant & Equipment $75.90M $72.80M
YoY Change -17.17% -14.52%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $118.9M $106.0M
YoY Change 38.22% 35.42%
Total Long-Term Assets $361.7M $348.3M
YoY Change 2.08% 1.65%
TOTAL ASSETS
Total Short-Term Assets $2.329B $2.416B
Total Long-Term Assets $361.7M $348.3M
Total Assets $2.691B $2.764B
YoY Change -9.42% -4.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.243M $13.08M
YoY Change -61.52% 24.6%
Accrued Expenses $114.3M $106.0M
YoY Change 9.15% -5.9%
Deferred Revenue $94.07M $130.4M
YoY Change -2.27% 41.23%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $44.00M $44.38M
YoY Change 394.22% 438.62%
Total Short-Term Liabilities $306.2M $327.6M
YoY Change 6.32% 26.4%
LONG-TERM LIABILITIES
Long-Term Debt $1.232B $1.231B
YoY Change -6.33% 3.93%
Other Long-Term Liabilities $41.77M $41.80M
YoY Change 154.16% 458.3%
Total Long-Term Liabilities $41.77M $41.80M
YoY Change 154.16% 458.3%
TOTAL LIABILITIES
Total Short-Term Liabilities $306.2M $327.6M
Total Long-Term Liabilities $41.77M $41.80M
Total Liabilities $2.427B $2.467B
YoY Change -4.54% 2.87%
SHAREHOLDERS EQUITY
Retained Earnings -$2.005B -$1.939B
YoY Change 22.31% 24.76%
Common Stock $2.304B $2.270B
YoY Change 8.74% 8.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $263.7M $296.5M
YoY Change
Total Liabilities & Shareholders Equity $2.691B $2.764B
YoY Change -9.42% -4.2%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$66.27M -$142.8M
YoY Change -22.31% 14.86%
Depreciation, Depletion And Amortization $3.087M $2.547M
YoY Change -5.25% -2.19%
Cash From Operating Activities -$119.9M -$149.9M
YoY Change 23.13% 11.9%
INVESTING ACTIVITIES
Capital Expenditures $6.234M $4.493M
YoY Change -48.1% -57.1%
Acquisitions
YoY Change
Other Investing Activities $68.68M $80.60M
YoY Change -15.75% -125.57%
Cash From Investing Activities $62.45M $76.11M
YoY Change -10.16% -123.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.557M 23.57M
YoY Change -98.22% -95.21%
NET CHANGE
Cash From Operating Activities -119.9M -149.9M
Cash From Investing Activities 62.45M 76.11M
Cash From Financing Activities 2.557M 23.57M
Net Change In Cash -54.87M -50.38M
YoY Change -147.43% -254.73%
FREE CASH FLOW
Cash From Operating Activities -$119.9M -$149.9M
Capital Expenditures $6.234M $4.493M
Free Cash Flow -$126.1M -$154.4M
YoY Change 15.3% 6.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-142803000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-124323000
CY2024Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-114000
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
104000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
31340000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26948000
CY2023Q1 ions Research Development And Patent Expense
ResearchDevelopmentAndPatentExpense
197813000
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
52644000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
45516000
CY2024Q1 us-gaap Costs And Expenses
CostsAndExpenses
269010000
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
244672000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-149513000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-114148000
CY2024Q1 us-gaap Investment Income Net
InvestmentIncomeNet
26285000
CY2023Q1 us-gaap Investment Income Net
InvestmentIncomeNet
18627000
CY2024Q1 us-gaap Interest Expense
InterestExpense
4151000
CY2023Q1 us-gaap Interest Expense
InterestExpense
1608000
CY2024Q1 ions Interest Expense And Amortization Of Issuance Costs Related To Sale Of Future Royalties
InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties
17959000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
75000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11380000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-142803000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-124323000
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.98
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.98
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.87
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.87
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
145538000
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
145538000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
142735000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
142735000
CY2024Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-2205000
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
8393000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-145122000
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000874015
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
119497000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
130524000
CY2024Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2151000
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1343000
CY2024Q1 ions Research Development And Patent Expense
ResearchDevelopmentAndPatentExpense
214215000
CY2023Q1 ions Interest Expense And Amortization Of Issuance Costs Related To Sale Of Future Royalties
InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties
15515000
CY2024Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
2333000
CY2023Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
-529000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
277000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
230000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-142728000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-112943000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-115826000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
119497000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
130524000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11400000

Files In Submission

Name View Source Status
0000874015-24-000142-index-headers.html Edgar Link pending
0000874015-24-000142-index.html Edgar Link pending
0000874015-24-000142.txt Edgar Link pending
0000874015-24-000142-xbrl.zip Edgar Link pending
ex10-1.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10q.htm Edgar Link pending
image01.jpg Edgar Link pending
ions-20240331.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
form10q_htm.xml Edgar Link completed
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ions-20240331_cal.xml Edgar Link unprocessable
ions-20240331_def.xml Edgar Link unprocessable
ions-20240331_lab.xml Edgar Link unprocessable
ions-20240331_pre.xml Edgar Link unprocessable